Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review

Frontiers in Immunology(2021)10.3389/fimmu.2021.771201Source: DataRank Database

Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 20 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access20 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.53)OA: goldTopics (61)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

C. F. Xu ORCID,Fengqian Chen ORCID,Qi Liu ORCID,Ning Cheng ORCID,Yanqi Ye ORCID

Live enrichment

PubMed:34899721 PMC:PMC8656691 OpenAlex:https://openalex.org/W3214869244

National Institutes of Health

Grant: CA223019

NCI NIH HHS

Grant: F99 CA223019

NCI NIH HHS

Grant: K00 CA223019

National Institutes of Health

Grant: 4K00CA223019-03

Particulate Delivery of STING Agonist as Anti-cancer Immuotherapeutics and Cancer Microbiome

FWCI

1.53

Citation Percentile

0.8%

Influential Citations

Citation Trend

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.771201/pdf

GOLDhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.771201/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.771201/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.771201/full

journalhttps://doi.org/10.3389/fimmu.2021.771201

Fields of Study

Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionMedicineBiology03 medical and health sciences0302 clinical medicineAdaptive ImmunityBreast NeoplasmsFemaleHumansImmunity, InnateImmunotherapyKiller Cells, NaturalLymphocytes, Tumor-InfiltratingMyeloid-Derived Suppressor CellsSignal TransductionT-Lymphocytes, RegulatoryTumor Microenvironment

MeSH Terms

Myeloid-Derived Suppressor CellsBreast NeoplasmsFemaleHumansImmunity, InnateImmunotherapyKiller Cells, NaturalSignal TransductionLymphocytes, Tumor-InfiltratingT-Lymphocytes, RegulatoryAdaptive ImmunityTumor Microenvironment

Keywords

Innate immune systemBreast cancerMedicineAcquired immune systemImmune systemTumor microenvironmentImmunologyImmunityImmunotherapyCancerMetastasisInternal medicineinnate immunityCancer ImmunotherapyClinical StudiesVaccine Adjuvants2403 ImmunologyMyeloid-Derived Suppressor CellsBreast NeoplasmsRC581-607Adaptive ImmunityT-Lymphocytes, RegulatoryImmunity, InnateKiller Cells, NaturalLymphocytes, Tumor-Infiltrating2723 Immunology and AllergyHumansFemaleImmunologic diseases. AllergySignal Transduction

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review

FAIR Checklist

Authors (5)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)